title: miR-142-3p inhibits cancer cell proliferation by targeting CDC25C.
abstract: OBJECTIVE
  MicroRNAs (miRNAs) contribute to control of cell cycle progression and are frequently deregulated in cancer. The focus of this study was to determine effects of miR-142-3p on the cell cycle progression and cancer cell proliferation.
  
  
  METHODS
  RT-qPCR was performed to determine expression of miR-142-3p in a range of cancer cell lines and in clinical cancer specimens. To further understand its role, we restored its expression in cancer cell lines by transfection with miR-142-3p mimics or inhibitors. Effects of miR-142-3p on cell cycle progression and cell proliferation were also determined.
  
  
  RESULTS
  miR-142-3p was down-regulated in both cancer cell lines and cancer specimens. Its overexpression suppressed proliferation, whereas its depletion promoted it. In addition, miR-142-3p lead to cell cycle arrest in G2/M. Moreover, CDC25C was identified as being a target of miR-142-3p, ectopic expression of which reversed suppression of cell proliferation.
  
  
  CONCLUSIONS
  Our observations suggest that miR-142-3p functioned as a tumor suppressor by targeting CDC25C.
authors.affiliation: First Department of Breast Cancer, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin, 300060, China.|Key Laboratory of Cancer Prevention and Therapy, Tianjin, 300060, China.|Key Laboratory of Breast Cancer Prevention and Therapy, Tianjin Medical University, Ministry of Education, Tianjin, 300060, China.
authors.forename: Xu-Chen
authors.initials: XC
authors.lastname: Cao
authors.affiliation: First Department of Breast Cancer, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin, 300060, China.|Key Laboratory of Cancer Prevention and Therapy, Tianjin, 300060, China.|Key Laboratory of Breast Cancer Prevention and Therapy, Tianjin Medical University, Ministry of Education, Tianjin, 300060, China.
authors.forename: Yue
authors.initials: Y
authors.lastname: Yu
authors.affiliation: First Department of Breast Cancer, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin, 300060, China.|Key Laboratory of Cancer Prevention and Therapy, Tianjin, 300060, China.|Key Laboratory of Breast Cancer Prevention and Therapy, Tianjin Medical University, Ministry of Education, Tianjin, 300060, China.
authors.forename: Li-Kun
authors.initials: LK
authors.lastname: Hou
authors.affiliation: First Department of Breast Cancer, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin, 300060, China.|Key Laboratory of Cancer Prevention and Therapy, Tianjin, 300060, China.|Key Laboratory of Breast Cancer Prevention and Therapy, Tianjin Medical University, Ministry of Education, Tianjin, 300060, China.
authors.forename: Xiao-Hu
authors.initials: XH
authors.lastname: Sun
authors.affiliation: First Department of Breast Cancer, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin, 300060, China.|Key Laboratory of Cancer Prevention and Therapy, Tianjin, 300060, China.|Key Laboratory of Breast Cancer Prevention and Therapy, Tianjin Medical University, Ministry of Education, Tianjin, 300060, China.
authors.forename: Jie
authors.initials: J
authors.lastname: Ge
authors.affiliation: First Department of Breast Cancer, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin, 300060, China.|Key Laboratory of Cancer Prevention and Therapy, Tianjin, 300060, China.|Key Laboratory of Breast Cancer Prevention and Therapy, Tianjin Medical University, Ministry of Education, Tianjin, 300060, China.
authors.forename: Bin
authors.initials: B
authors.lastname: Zhang
authors.affiliation: First Department of Breast Cancer, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin, 300060, China.|Key Laboratory of Cancer Prevention and Therapy, Tianjin, 300060, China.|Key Laboratory of Breast Cancer Prevention and Therapy, Tianjin Medical University, Ministry of Education, Tianjin, 300060, China.
authors.forename: Xin
authors.initials: X
authors.lastname: Wang
mesh_terms: D001483:Base Sequence; D059447:Cell Cycle Checkpoints; D045744:Cell Line, Tumor; D049109:Cell Proliferation; D015536:Down-Regulation / Q000235:genetics; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D035683:MicroRNAs / Q000235:genetics / Q000378:metabolism*; D008969:Molecular Sequence Data; D009369:Neoplasms / Q000235:genetics* / Q000473:pathology*; D020687:cdc25 Phosphatases / Q000378:metabolism*
chemical_list: C555159:MIRN142 microRNA, human; D035683:MicroRNAs; C517009:CDC25C protein, human; D020687:cdc25 Phosphatases